Published in J Immunol on September 15, 1997
A transgenic mouse model to analyze CD8(+) effector T cell differentiation in vivo. Proc Natl Acad Sci U S A (1999) 1.62
Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A (2000) 1.46
Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation. J Virol (2000) 1.38
T cells in rheumatoid arthritis. Arthritis Res Ther (2008) 1.33
Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis (2001) 1.24
Effect of redox balance alterations on cellular localization of LAT and downstream T-cell receptor signaling pathways. Mol Cell Biol (2002) 1.17
Methamphetamine causes mitrochondrial oxidative damage in human T lymphocytes leading to functional impairment. J Immunol (2010) 1.14
Down-regulation of the T cell receptor CD3 zeta chain in rheumatoid arthritis (RA) and its influence on T cell responsiveness. Clin Exp Immunol (2000) 1.05
Studies of T-cell activation in chronic inflammation. Arthritis Res (2002) 1.04
T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res Ther (2012) 1.03
Adding fuel to the fire: methamphetamine enhances HIV infection. Am J Pathol (2008) 1.00
What does tumour necrosis factor excess do to the immune system long term? Ann Rheum Dis (2005) 0.98
CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. J Clin Invest (1998) 0.93
High avidity autoreactive T cells with a low signalling capacity through the T-cell receptor: central to rheumatoid arthritis pathogenesis? Arthritis Res Ther (2008) 0.88
Low levels of NF-κB/p65 mark anergic CD4+ T cells and correlate with disease severity in sarcoidosis. Clin Vaccine Immunol (2010) 0.88
Altered gene expression in blood and sputum in COPD frequent exacerbators in the ECLIPSE cohort. PLoS One (2014) 0.86
T cell receptor zeta reconstitution fails to restore responses of T cells rendered hyporesponsive by tumor necrosis factor alpha. Proc Natl Acad Sci U S A (2004) 0.85
Interleukin-15 up-regulates the expression of CD154 on synovial fluid T cells. Immunology (2000) 0.85
Down regulation of T cell receptor expression in COPD pulmonary CD8 cells. PLoS One (2013) 0.84
Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients. Clin Exp Immunol (2002) 0.82
Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med (2011) 0.81
Decreased expression of the CD3zeta chain in T cells infiltrating the synovial membrane of patients with osteoarthritis. Clin Diagn Lab Immunol (2004) 0.81
Opposing effects of low molecular weight heparins on the release of inflammatory cytokines from peripheral blood mononuclear cells of asthmatics. PLoS One (2015) 0.81
Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes. Br J Cancer (1999) 0.80
T cell CD3ζ deficiency enables multiorgan tissue inflammation. J Immunol (2013) 0.80
Differential requirements for induction of total immunoglobulin and physiological rheumatoid factor production by human peripheral blood B cells. Clin Exp Immunol (2001) 0.79
Association of CD247 polymorphisms with rheumatoid arthritis: a replication study and a meta-analysis. PLoS One (2013) 0.78
Biased T-cell antigen receptor repertoire in Lyme arthritis. Infect Immun (1998) 0.77
Current perspectives on synovitis. Arthritis Res (1999) 0.77
Gene Expression Profile of T-cell Receptors in the Synovium, Peripheral Blood, and Thymus during the Initial Phase of Collagen-induced Arthritis. Immune Netw (2011) 0.75
Harmful waste products as novel immune modulators for treating inflammatory arthritis? PLoS Med (2006) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum (2000) 8.64
Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med (1997) 8.59
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum (2005) 8.47
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Genetic influence on cytokine production and fatal meningococcal disease. Lancet (1997) 4.89
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science (1989) 4.70
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med (2001) 4.31
Influence of non-inherited maternal HLA antigens on occurrence of rheumatoid arthritis. Lancet (1993) 3.87
CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol (2000) 3.84
Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum (1997) 3.80
Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol (1990) 3.55
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum (2004) 3.38
Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum (1999) 3.08
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Functional and phenotypic evidence for a selective loss of memory T cells in asymptomatic human immunodeficiency virus-infected men. J Clin Invest (1990) 2.51
Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res (1985) 2.50
Synovial fluid T cell reactivity against 65 kD heat shock protein of mycobacteria in early chronic arthritis. Lancet (1988) 2.43
Detection of bacterial DNA in joint samples from patients with undifferentiated arthritis and reactive arthritis, using polymerase chain reaction with universal 16S ribosomal RNA primers. Arthritis Rheum (1998) 2.41
Factors predicting outcome of rheumatoid arthritis: results of a followup study. J Rheumatol (1993) 2.40
Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 2.37
Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J (1986) 2.35
Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet (1996) 2.30
Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol (2014) 2.28
Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum (1995) 2.25
Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum (1998) 2.24
Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis (2005) 2.23
Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis (2007) 2.22
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2000) 2.19
Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A (1998) 2.18
Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum (2000) 2.14
Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2001) 2.11
Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum (2007) 2.10
Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation. Nature (1988) 2.09
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum (2008) 2.07
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
[Arthroscopic lavage plus corticosteroids is more effective than joint aspiration plus corticosteroids in patients with arthritis of the knee]. Ned Tijdschr Geneeskd (2008) 2.05
Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm (1997) 2.05
Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum (2004) 2.05
Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.03
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol (1999) 1.99
The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med (1996) 1.99
The Leiden Early Arthritis Clinic. Clin Exp Rheumatol (2004) 1.97
Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum (1995) 1.93
Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J Immunol (1987) 1.92
Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum (2007) 1.90
Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity (2001) 1.90
Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum (2002) 1.87
DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis (2010) 1.87
Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum (2011) 1.86
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 1.84
Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) (2003) 1.83
Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum (2011) 1.83
Regulation of CD27 expression on subsets of mature T-lymphocytes. J Immunol (1993) 1.83
Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol (1995) 1.79
Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods (2011) 1.78
Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J (1986) 1.78
Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol (1998) 1.78
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum (2009) 1.76
Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford) (2000) 1.76
Evidence that human CD8+CD45RA+CD27- cells are induced by antigen and evolve through extensive rounds of division. Int Immunol (1999) 1.75
An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun (1999) 1.75
Heterogeneity of the circulating human CD4+ T cell population. Further evidence that the CD4+CD45RA-CD27- T cell subset contains specialized primed T cells. J Immunol (1995) 1.74
Long term high intensity exercise and damage of small joints in rheumatoid arthritis. Ann Rheum Dis (2004) 1.73
Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis (2009) 1.72
Comparison of the responsiveness of the Harris Hip Score with generic measures for hip function in osteoarthritis of the hip. Ann Rheum Dis (2003) 1.71
Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis (2010) 1.71
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun (2003) 1.70
Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis (2007) 1.68
Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis (1992) 1.68
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis (2005) 1.66
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol (1997) 1.63
The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis (2007) 1.63
Human atopen-specific types 1 and 2 T helper cell clones. J Immunol (1991) 1.62